Minimally invasive weight loss device maker quietly raises $2.75 million
Although it’s trying to keep quiet about its product, a medical device startup developing a new treatment for obesity revealed this week it’s in the middle of raising $5.5 …
View ArticleClik here to view.
Relypsa Gets Another $50M for Drug to Fight Excess Potassium
Luke Timmerman Relypsa has soaked up a whole lot more venture capital to push its lead drug candidate through the later stages of clinical trials. The Santa Clara, CA-based biotech …
View ArticleClik here to view.
Relypsa snatches $80M for drug to treat high potassium in kidney disease,...
Name of Company: Relypsa Inc. Industry: Biopharmaceuticals City, State: Santa Clara, California Solution/Product: Patiromer, or RLY5016, is a non-absorbed oral potassium binder being developed for the...
View ArticleSequent Medical, Inc.: Series C $26M
Sequent Medical (Aliso Viejo, CA) a commercial-stage medical device company focused on endovascular embolic coils devices for ruptured and non-ruptured intracranial aneurysms, closed a $26M Series C...
View ArticleClik here to view.
Karyopharm Grabs $48.2M Series B to Advance Cancer Drugs
Ben Fidler Karyopharm Therapeutics believes it can build a platform of cancer drugs off of the idea of keeping the body’s tumor-suppressing proteins in the nucleus of cells, where they …
View ArticleClik here to view.
Cardeas Pharma Snags $34M For Antibiotic Against Hospital Infections
Luke Timmerman Seattle-based Cardeas Pharma just raised a lot more cash to fight a big problem that hospitals wrestle with every day, and which they’d rather not say much about …
View ArticleClik here to view.
OncoMed Pharmaceuticals Soars in IPO Debut
Luke Timmerman The stock market can’t seem to get enough of biotech IPOs these days, and OncoMed Pharmaceuticals is the latest company to cash in. Redwood City, CA-based OncoMed Pharmaceuticals …
View ArticleClik here to view.
Karyopharm Enters IPO Queue, Plots up to $80M Raise For Cancer Drug
Ben Fidler Karyopharm Therapeutics raised close to $50 million just a few months ago to continue developing its lead cancer drug. Now it’s turning to Wall Street to help with …
View ArticleClik here to view.
Insulin Pump Maker Tandem Diabetes Plans to Raise $100M Through IPO
Bruce V. Bigelow Joining a procession of life sciences IPOs, San Diego’s Tandem Diabetes Care has registered to raise about $100 million through an initial public offering, according to a …
View ArticleClik here to view.
Calithera BioSciences Nabs $35M for Cancer Drugs
Luke Timmerman South San Francisco-based Calithera Biosciences has just raised a lot more money to add its name to the list of companies that hope to fight tumors by starving …
View ArticleClik here to view.
Karyopharm Prices Upsized IPO at $16 Per Share, Begins Trading Today
Ben Fidler Karyopharm Therapeutics got a warm welcome from investors last night. The Natick, MA-based biotech said late Tuesday that it priced its IPO at $16 per share, at …
View ArticleClik here to view.
Alder BioPharmaceuticals Hits IPO Trail Looking for $115M
Ben Fidler Alder BioPharmaceuticals grabbed some headlines late last year when a rheumatoid arthritis drug it’s been developing with Bristol-Myers Squibb showed some early signs that it might have a …
View ArticleBiotech IPO Slump Deepens as Alder Prices Below Range
Ben Fidler As Alder Biopharmaceuticals can attest to today, the biotech IPO train has hit the skids. The Bothell, WA-based company has priced its IPO at $10 per share, well …
View ArticleClik here to view.
FDA OKs Astute Medical’s First Diagnostic for Acute Kidney Injury
Bruce V. Bigelow San Diego-based Astute Medical, founded in 2007 to identify and validate protein biomarkers that can be used to improve the diagnosis of high-risk medical conditions, says …
View ArticleClik here to view.
VC Funding Still Robust as Year-to-Date Total Exceeds 2013
Bruce V. Bigelow Venture capital activity is down from a 13-year high during the second quarter, but a new MoneyTree Report released today shows that venture funding was still going (Read more...)
View Article
